DOI: https://dx.doi.org/10.18565/pharmateca.2023.11.37-43
Гаврилова Д.А., Бесова Н.С., Обаревич Е.С., Макиев Г.Г., Трякин А.А., Стилиди И.С.
Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина, Москва, Россия
1. Smyth E.C., Nilsson M., Grabsch H.I., et al. Gastric cancer. Lancet. 2020;396(10251):635–48. Doi: 10.1016/s0140-6736(20)31288-5.
2. Joshi S.S., Badgwell B.D. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79. Doi: 10.3322/caac.21657.
3. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. Doi: 10.1056/NEJMoa073149.
4. Guimbaud R., Louvet Ch., Ries P., et al. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup Study. J Clin Oncol. 2014;32:3520–26.
5. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.
6. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.
7. Digklia A., Wagner A.D. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14. Doi: 10.3748/wjg.v22.i8.2403.
8. Enzinger P.C., Burtness B.A., Niedzwiecki D., аt al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34(23):2736–42. Doi: 10.1200/JCO.2015.65.5092.
9. Shah M.A., Bang Y., Lordick F., et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. The METGastric Randomized Clinical Trial. JAMA Oncol. 2017;3(5):620–27. Doi: 10.1001/jamaoncol.2016.5580.
10. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21. Doi: 10.1016/S1470-2045(08)70035-4.
11. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–97.
12. Cutsem E.V., Boni C., Tabernero J., et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26(1):149–56. Doi: 10.1093/annonc/mdu496.
13. Shah M.A., Janjigian Y.Y., Stoller R., et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874–79. Doi: 10.1200/JCO.2015.60.7465.
14. Park H., Jin R.U., Wang-Gillam A., et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020;6(8):1231–40. Doi: 10.1001/jamaoncol.2020.2020.
15. Comella P., Lorusso V., Maiorino L., et al. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol. 2009;64(5):893–99. Doi: 10.1007/s00280-009-0938-4.
16. Cao W., Yang W., Lou G., et al. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009;20(4):287–93. Doi: 10.1097/CAD.0b013e3283273509.
17. Lee J., Kang W.K., Kwon J.M., et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(1):88–92. Doi: 10.1093/annonc/mdl317.
18. Chiesa M.D., Buti S., Tomasello G., et al. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil andirinotecan in metastatic gastric cancer. Tumori. 2007;93(3):244–47. Doi: 10.1177/030089160709300303.
19. Peinert S., Grothe W., Stein A., et al. Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther Adv Med Oncol. 2010;2(3):161–74. Doi: 10.1177/1758834010365061.
20. Shrestha A., Martin C., Burton M., et al. Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology. 2019;28(7):1367–80. Doi: 10.1002/pon.5054.
21. Heydarnejad M.S., Hassanpour D.A., Solati D.K. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr. Health Sci. 2011;11(2):266–70.
22. Ramasubbu S.K., Pasricha R.K., Nath U.K., et al. Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep. (Hoboken). 2021;4(2):e1312. Doi: 10.1002/cnr2.1312.
23. Lewandowska A., Rudzki G., Lewandowski T., et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. 2020;17(19):6938. Doi: 10.3390/ijerph17196938.
24. CONSORT Transparent reporting of trials. URL: http:// www.consort-statement.org/about-consort (access date: 17.04.2019).
25. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;9(8):672–77. Doi: 10.1016/j.ijsu.2011.09.004.
26. Schwartz L.H., Litiere S., Vries E. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–37. Doi: 10.1016/j.ejca.2016.03.081.
27. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute.
Автор для связи: Георгий Георгиевич Макиев, аспирант отделения противоопухолевой лекарственной терапии № 2 отдела лекарственных
методов лечения НИИ КО им. акад. РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии
им. Н.Н. Блохина, Москва, Россия
ORCID / SPIN ID / Scopus Author ID:
Д.А. Гаврилова (D.A. Gavrilova), https://orcid.org/0009-0008-5996-6965
Н.С. Бесова (N.S. Besova), https://orcid.org/0000-0002-1693-0523, SPIN ID: 7464-5830
Е.С. Обаревич (E.S. Obarevich), https://orcid.org/0000-0001-9885-3922
Г.Г. Макиев (G.G. Makiev), https://orcid.org/0000-0001-9732-4033
А.А. Трякин (A.A. Tryakin), https://orcid.org/0000-0003-2245-214X; WOS AAJ-4456-2021; Scopus Author ID: 55778910600; РИНЦ–SPIN: 8638-3526
И.С. Стилиди (I.S. Stilidi), https://orcid.com/0000-0002-0493-1166; Scopus Author ID: 6602949492; РИНЦ–SPIN: 9622-7106; Author ID: 443520